Jinping Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinping Li has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Bin Liu
RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.
11 shared publications - Boyang Ma
University of Massachusetts Chan Medical School 1 Department of Molecular, Cell, and Cancer Biology Worcester, Massachusetts
11 shared publications - Calvin Johnson
University of Massachusetts Chan Medical School 3 Division of Hematology-Oncology, Department of Medicine Worcester, Massachusetts
11 shared publications - Chaitanya N. Parikh
University of Massachusetts Chan Medical School 1 Department of Molecular, Cell, and Cancer Biology Worcester, Massachusetts
11 shared publications - Hadiya K. Giwa
University of Massachusetts Chan Medical School 1 Department of Molecular, Cell, and Cancer Biology Worcester, Massachusetts
11 shared publications - Hong Wu
The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing, China
11 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 5 shows that tumor cell-specific p16 or p21 knockout enhances DC and CD8+ T cell accumulation but has no effect on the SASP or T cell activity in transplanted prostate tumors.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 5 shows that tumor cell-specific p16 or p21 knockout enhances DC and CD8+ T cell accumulation but has no effect on the SASP or T cell activity in transplanted prostate tumors.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Data from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Cellular senescence is a well-established tumor-suppressive cell-cycle arrest program. However, chronic inflammation through the senescence-associated secretory phenotype (SASP) can alternatively drive immune suppression and cancer progression. Using prostate cancer patient samples and murine models, we find p16+ and p21+ senescent cells accumulate throughout malignant progression and associate with immune suppression. Single-cell sequencing revealed that p16 and p21 mark distinct epithelial and stromal senescent populations, with p21+ nontumor cells expressing the highest SASP. p21+ stromal cell removal blocked the SASP to reverse immune suppression and slow tumor growth. Senolytic BCL-xL inhibitor treatment could clear p21+ stromal senescent cells, reactivating antitumor CD8+ T-cell immunity and inhibiting prostate tumor progression in mice. Suppression of BCL-xL or p21 also potentiated anti–PD-1 immune checkpoint blockade (ICB) in preclinical prostate cancer models. Our findings demonstrate that targeting p21+ senescent stromal populations can yield therapeutic benefits in advanced prostate cancer through activating antitumor immunity and enhancing immunotherapy outcomes.Significance:Senescent cells accumulate in the tumor and stroma throughout prostate cancer progression and are associated with immune suppression in patients and mice. Senolytic strategies to clear p21+ senescent stromal cells can prevent prostate cancer progression and reactive cytotoxic T-cell immunity to potentiate anti–PD-1 ICB in advanced disease.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Cellular senescence is a well-established tumor-suppressive cell-cycle arrest program. However, chronic inflammation through the senescence-associated secretory phenotype (SASP) can alternatively drive immune suppression and cancer progression. Using prostate cancer patient samples and murine models, we find p16+ and p21+ senescent cells accumulate throughout malignant progression and associate with immune suppression. Single-cell sequencing revealed that p16 and p21 mark distinct epithelial and stromal senescent populations, with p21+ nontumor cells expressing the highest SASP. p21+ stromal cell removal blocked the SASP to reverse immune suppression and slow tumor growth. Senolytic BCL-xL inhibitor treatment could clear p21+ stromal senescent cells, reactivating antitumor CD8+ T-cell immunity and inhibiting prostate tumor progression in mice. Suppression of BCL-xL or p21 also potentiated anti–PD-1 immune checkpoint blockade (ICB) in preclinical prostate cancer models. Our findings demonstrate that targeting p21+ senescent stromal populations can yield therapeutic benefits in advanced prostate cancer through activating antitumor immunity and enhancing immunotherapy outcomes.Significance:Senescent cells accumulate in the tumor and stroma throughout prostate cancer progression and are associated with immune suppression in patients and mice. Senolytic strategies to clear p21+ senescent stromal cells can prevent prostate cancer progression and reactive cytotoxic T-cell immunity to potentiate anti–PD-1 ICB in advanced disease.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 6 shows that p16 ablation in the stroma has no impact on prostate tumor or immune responses.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 6 shows that p16 ablation in the stroma has no impact on prostate tumor or immune responses.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 8 shows that ABT-263 and anti-PD-1 combination therapy reduces senescent cell accumulation, fibrosis, and myeloid cell recruitment in advanced prostate cancer, culminating in enhanced animal survival.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 8 shows that ABT-263 and anti-PD-1 combination therapy reduces senescent cell accumulation, fibrosis, and myeloid cell recruitment in advanced prostate cancer, culminating in enhanced animal survival.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 7 shows that ABT-263 preferentially targets p21+ stromal cells, leading to reduced pro-myeloid SASP expression and immature myeloid cells and enhanced cytotoxic lymphocyte immunity.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 7 shows that ABT-263 preferentially targets p21+ stromal cells, leading to reduced pro-myeloid SASP expression and immature myeloid cells and enhanced cytotoxic lymphocyte immunity.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 4 shows that GCV-mediated ablation of p16+ senescent epithelial cells fails to repress the SASP or fully activate NK and CD8+ T cells in CP-3MR prostates.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 4 shows that GCV-mediated ablation of p16+ senescent epithelial cells fails to repress the SASP or fully activate NK and CD8+ T cells in CP-3MR prostates.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 and Table S2 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Table S1 shows sgRNA sequences. Supplementary Table S2 shows RT-qPCR primer sequences.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 and Table S2 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Table S1 shows sgRNA sequences. Supplementary Table S2 shows RT-qPCR primer sequences.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 2 shows that p16 and p21 expression in human prostate cancers correlates with poor CD8+ T cell infiltration.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 2 shows that p16 and p21 expression in human prostate cancers correlates with poor CD8+ T cell infiltration.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 3 shows that p21+ cells have a different stromal localization and SASP profile compared to p16+ cells in CP mouse prostate tumors.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 3 shows that p21+ cells have a different stromal localization and SASP profile compared to p16+ cells in CP mouse prostate tumors.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 1 shows that senescent cells are found in tumor and stromal areas of CP prostates and track with immune suppression during disease progression.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 1 shows that senescent cells are found in tumor and stromal areas of CP prostates and track with immune suppression during disease progression.